Companies/MannKind Corporation

Company profile

MannKind Corporation

NASDAQ: MNKD · Healthcare · Biotechnology

PublicHQ Danbury, CACIK 0000899460Reports USD

#233 of 1,394 Healthcare companies by revenue69th-percentile growth

EA Score

69B

FH 58DQ 81GM 72SS 80

v0.1 · 65/100 weight · provisional

↑ operating margin, disclosure history · ↓ Piotroski F, balance-sheet leverage

Methodology →

Revenue TTM

$360.8M

Rev growth YoY (TTM)

+21.2%

Net income (FY)

$5.9M

Employees

403

Market cap

$1.4B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$349.0M$349.0M2025

Net income$5.9M$5.9M2025

Operating income$38.8M$38.8M2025

Total assets$792.2M$792.2M2025

Liabilities$843.2M$843.2M2025

Equity-$51.0M-$51.0M2025

Revenue trend

FY2019 – FY2025 · USD

$14.6M

FY19

$63.0M

FY19

$65.1M

FY20

$75.4M

FY21

$99.8M

FY22

$199.0M

FY23

$285.5M

FY24

$349.0M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Product Revenue62%

Royalty37%

Service1%

By geography

Not disclosed.

The read

MannKind Corporation booked $349.0M in FY2025 revenue, growing 22% year over year — faster than most Healthcare companies we track, at a 1.7% net margin.

Peers · Healthcare

Integra LifeSciences Holdings Corporation67B Nektar Therapeutics50D STAAR Surgical Company67B BioLife Solutions, Inc.74B

Key facts

CEOMichael E. Castagna

SectorHealthcare

IndustryBiotechnology

HeadquartersDanbury, CA

ExchangeNASDAQ: MNKD

Employees403

IPO date2004-07-28

Latest filings

8-K2026-06-02 8-K2026-05-28 8-K2026-05-22 10-Q2026-05-06 8-K2026-05-06 DEF 14A2026-04-07 8-K2026-02-26 10-K2026-02-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.